Cardio Diagnostics Holdings (CDIO) Liabilities and Shareholders Equity (2021 - 2026)

Cardio Diagnostics Holdings has reported Liabilities and Shareholders Equity for 6 years, with the latest figure at $9.6 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 22.17% year-over-year to $9.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $36.5 million (up 16.37% YoY) and the FY2025 annual result came in at $7.8 million, down 26.84% from the prior year.
• Liabilities and Shareholders Equity grew to $9.6 million in Q1 2026 per CDIO's latest filing, from $7.8 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $65.8 million in Q3 2022 and troughed at $4.0 million in Q2 2024.
• A 5-year average of $17.7 million and a median of $8.6 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity surged 467.11% in 2022, then tumbled 90.94% in 2023.
• Over 5 years, Liabilities and Shareholders Equity stood at $6.2 million in 2022, then decreased by 28.6% to $4.5 million in 2023, then jumped by 137.89% to $10.6 million in 2024, then dropped by 26.84% to $7.8 million in 2025, then advanced by 23.09% to $9.6 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $9.6 million, $7.8 million, and $8.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.